Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease
暂无分享,去创建一个
L. Wallentin | K. Winters | C. Ernest | R. Wrishko | S. Rohatagi | D. Small | D. Salazar
[1] N. Farid,et al. Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. , 2008, Journal of pharmaceutical and biomedical analysis.
[2] Jeffrey L. Anderson,et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[3] L. Wallentin,et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. , 2007, Cardiovascular drug reviews.
[4] S. Iturria,et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.
[5] A. Siegbahn,et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. , 2007, European heart journal.
[6] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[7] K. Winters,et al. Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel , 2007, Journal of cardiovascular pharmacology.
[8] K. Winters,et al. Dose-Dependent Inhibition of Human Platelet Aggregation by Prasugrel and its Interaction With Aspirin in Healthy Subjects , 2007, Journal of cardiovascular pharmacology.
[9] M. Young,et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. , 2007, Rapid communications in mass spectrometry : RCM.
[10] M. Furman,et al. Current options in platelet function testing. , 2006, The American journal of cardiology.
[11] A. Kastrati,et al. Impact of P‐glycoprotein on clopidogrel absorption , 2006, Clinical pharmacology and therapeutics.
[12] A. Bura,et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.
[13] A. Siegbahn,et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. , 2006, European heart journal.
[14] B. Ring,et al. INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450 , 2006, Drug Metabolism and Disposition.
[15] Lippincott Williams Wilkins,et al. ACC/AHA/SCAI Practice Guidelines, February 21, 2006 , 2006 .
[16] J. Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.
[17] A. Kastrati,et al. Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial , 2005, Circulation.
[18] E. Antman,et al. Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial , 2005, Circulation.
[19] V. Pasceri,et al. Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study* , 2005, Circulation.
[20] J. Jakubowski,et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. , 2005, Seminars in thrombosis and hemostasis.
[21] J. Herbert,et al. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. , 2005, Seminars in thrombosis and hemostasis.
[22] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[23] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[24] J. W. Schaeffer,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article , 2002 .
[25] J. Herbert,et al. Identification and Biological Activity of the Active Metabolite of Clopidogrel , 2000, Thrombosis and Haemostasis.
[26] M. Bertrand,et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.
[27] U. Walter,et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[28] H. Kotaki,et al. Analysis of Antiplatelet Effect of Ticlopidine In Humans: Modeling Based on Irreversible Inhibition of Platelet Precursors in Bone Marrow , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[29] T. Ryan. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.
[30] R. Harrington. “Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study” , 2005 .
[31] R. de Caterina,et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. , 2004, European heart journal.
[32] L. Waskell,et al. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[33] E. Falk,et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. , 2003, European heart journal.
[34] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .
[35] R. Lins,et al. Pharmacokinetic profile of 14C-labeled clopidogrel. , 1999, Seminars in thrombosis and hemostasis.
[36] D. Green. Current trends in the use of heparins in thromboprophylaxis. , 1999, Seminars in thrombosis and hemostasis.